Cargando…

Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis

BACKGROUND: Dendritic cells (DCs) are used in many malignancies as vaccines to induce immunity against specific cancer antigens. The role of DCs in metastatic castration-resistant prostate cancer (mCRPC) is not determined. In this study, the proportion of mCRPC patients with clinically significant r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadzadeh, Mohammad, Shirmohammadi, Masoud, Ghojazadeh, Morteza, Nikniaz, Leila, Raeisi, Mortaza, Aghdas, Seyed Ali Mousavi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251944/
https://www.ncbi.nlm.nih.gov/pubmed/30505813
http://dx.doi.org/10.1016/j.prnil.2018.04.001
_version_ 1783373180211036160
author Mohammadzadeh, Mohammad
Shirmohammadi, Masoud
Ghojazadeh, Morteza
Nikniaz, Leila
Raeisi, Mortaza
Aghdas, Seyed Ali Mousavi
author_facet Mohammadzadeh, Mohammad
Shirmohammadi, Masoud
Ghojazadeh, Morteza
Nikniaz, Leila
Raeisi, Mortaza
Aghdas, Seyed Ali Mousavi
author_sort Mohammadzadeh, Mohammad
collection PubMed
description BACKGROUND: Dendritic cells (DCs) are used in many malignancies as vaccines to induce immunity against specific cancer antigens. The role of DCs in metastatic castration-resistant prostate cancer (mCRPC) is not determined. In this study, the proportion of mCRPC patients with clinically significant response to targeted therapy by DCs pulsed with prostate-specific membrane antigen was evaluated, and the possible adverse effects of this modality were investigated. METHODS: Major databases were searched up to Feb 2017, to identify studies in which the antitumor efficacy of DCs pulsed with the extracellular portion of PSMA was studied for the treatment of mCRPC. Data were collected by two reviewers and analyzed using Comprehensive Meta-Analysis software, version 2.0. FINDINGS: Our study consisted of 6 nonrandomized prospective (cohort) trials, overall reporting on 153 mCRPC patients. The event rate that is the representative of fraction of patients showing antitumor response was 0.43 (95% confidence interval = 0.355–0.512; P = 0.097). No significant between-study heterogeneity or inconsistency was detected (I(2) = 5.47; Q = 5; P = 0.382). Our study failed to demonstrate a significant therapeutic efficacy for DCs in mCRPC. However, no significant adverse effects were seen.
format Online
Article
Text
id pubmed-6251944
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Asian Pacific Prostate Society
record_format MEDLINE/PubMed
spelling pubmed-62519442018-11-30 Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis Mohammadzadeh, Mohammad Shirmohammadi, Masoud Ghojazadeh, Morteza Nikniaz, Leila Raeisi, Mortaza Aghdas, Seyed Ali Mousavi Prostate Int Review Article BACKGROUND: Dendritic cells (DCs) are used in many malignancies as vaccines to induce immunity against specific cancer antigens. The role of DCs in metastatic castration-resistant prostate cancer (mCRPC) is not determined. In this study, the proportion of mCRPC patients with clinically significant response to targeted therapy by DCs pulsed with prostate-specific membrane antigen was evaluated, and the possible adverse effects of this modality were investigated. METHODS: Major databases were searched up to Feb 2017, to identify studies in which the antitumor efficacy of DCs pulsed with the extracellular portion of PSMA was studied for the treatment of mCRPC. Data were collected by two reviewers and analyzed using Comprehensive Meta-Analysis software, version 2.0. FINDINGS: Our study consisted of 6 nonrandomized prospective (cohort) trials, overall reporting on 153 mCRPC patients. The event rate that is the representative of fraction of patients showing antitumor response was 0.43 (95% confidence interval = 0.355–0.512; P = 0.097). No significant between-study heterogeneity or inconsistency was detected (I(2) = 5.47; Q = 5; P = 0.382). Our study failed to demonstrate a significant therapeutic efficacy for DCs in mCRPC. However, no significant adverse effects were seen. Asian Pacific Prostate Society 2018-12 2018-04-28 /pmc/articles/PMC6251944/ /pubmed/30505813 http://dx.doi.org/10.1016/j.prnil.2018.04.001 Text en © 2018 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Mohammadzadeh, Mohammad
Shirmohammadi, Masoud
Ghojazadeh, Morteza
Nikniaz, Leila
Raeisi, Mortaza
Aghdas, Seyed Ali Mousavi
Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
title Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
title_full Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
title_fullStr Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
title_full_unstemmed Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
title_short Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
title_sort dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251944/
https://www.ncbi.nlm.nih.gov/pubmed/30505813
http://dx.doi.org/10.1016/j.prnil.2018.04.001
work_keys_str_mv AT mohammadzadehmohammad dendriticcellspulsedwithprostatespecificmembraneantigeninmetastaticcastrationresistantprostatecancerpatientsasystematicreviewandmetaanalysis
AT shirmohammadimasoud dendriticcellspulsedwithprostatespecificmembraneantigeninmetastaticcastrationresistantprostatecancerpatientsasystematicreviewandmetaanalysis
AT ghojazadehmorteza dendriticcellspulsedwithprostatespecificmembraneantigeninmetastaticcastrationresistantprostatecancerpatientsasystematicreviewandmetaanalysis
AT nikniazleila dendriticcellspulsedwithprostatespecificmembraneantigeninmetastaticcastrationresistantprostatecancerpatientsasystematicreviewandmetaanalysis
AT raeisimortaza dendriticcellspulsedwithprostatespecificmembraneantigeninmetastaticcastrationresistantprostatecancerpatientsasystematicreviewandmetaanalysis
AT aghdasseyedalimousavi dendriticcellspulsedwithprostatespecificmembraneantigeninmetastaticcastrationresistantprostatecancerpatientsasystematicreviewandmetaanalysis